STAT Plus: AstraZeneca aims to carve into Merck’s immunotherapy dominance
KIRSTY WIGGLESWORTH/AP
New data in lung cancer will likely lead to speculation as to whether Merck can hold onto its dominance with its treatment, Keytruda.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario